Scope and Claims Analysis of U.S. Patent 10,722,456
Overview
U.S. Patent 10,722,456, issued on July 28, 2020, to Eli Lilly and Company, covers novel compounds and methods for treating diseases through specific chemical entities. The patent primarily relates to kinase inhibitors targeting cancer and inflammatory conditions. Its protected scope encompasses particular chemical structures, their synthesis routes, and their use in pharmaceutical compositions.
Claims Overview
The patent contains 15 claims centered on chemical compounds with specific structural features. The claims fall into the following categories:
-
Compound Claims: Cover compounds with a core structure defined by a pyrimidine or pyridopyrimidine scaffold, modified at certain positions with substituents such as fluorine, methyl, or amino groups.
-
Method of Use: Claims covering methods of treating diseases, especially cancer, by administering compounds claimed in the patent.
-
Chemical Composition: Claims related to the pharmaceutical compositions containing these compounds with suitable carriers.
-
Synthesis and Formulation: Claims describing processes for synthesizing the compounds.
Claim Construction Details
Most claims are product-by-process or product claims focusing on compounds characterized by a chemical formula (e.g., formula I). Key features include:
-
Substituents: Specific configurations at designated positions, such as halogens, methyl, or amino groups.
-
Pharmacophore: The kinase inhibitory activity is rooted in the core heterocyclic structure conferred by the claimed compounds.
-
Range of Variations: The claims encompass variations on the substituents to cover a broad chemical space, increasing patent scope.
Scope Limitations
The claims' scope is limited to:
-
Specific chemical structures defined within the formulas provided.
-
Substituents specified in the dependent claims, narrowing the broad independent claims.
-
Pathways of administration and treatment methods, which do not extend beyond the compounds themselves.
Novelty and Inventive Step
The claims are supported by prior art disclosing kinase inhibitors and related heterocyclic compounds, but the patent distinguishes itself through specific substitutions, synthesis methods, and anticipated therapeutic applications. The inventive step relies on the particular combination of substituents leading to improved kinase selectivity or pharmacokinetics.
Patent Landscape for Similar Compounds and Therapeutics
Major Competitors and Patent Filings
-
Novartis, Pfizer, and Merck: Hold extensive patent portfolios for kinase inhibitors, especially targeting JAK, FGFR, and PI3K pathways.
-
Recent Publications: Patent families describe heterocyclic compounds similar to the scope of 10,722,456, focusing on structure-activity relationships (SAR) and selective kinase inhibition.
-
Patent Litigation and Freedom to Operate (FTO): The scope overlaps with existing kinase inhibitor patents, requiring careful FTO analysis for commercial development.
Similar Patent Families
-
Patent families around pyrimidine derivatives targeting kinase pathways in cancer treatment (e.g., WO2019112233, US2019278183).
-
Claims often include heterocyclic core modifications with extensive substituent variations for optimization.
Patent Trends
-
Emphasis on compounds with high selectivity, low toxicity, and improved pharmacokinetic profiles.
-
Integration of molecular modeling and SAR studies to extend patent claims' scope and durability.
-
Shifts toward targeted therapies that inhibit specific kinase isoforms, broadening patent protection.
Legal and Patentability Considerations
-
Patentability hinges on the novelty of specific substituents and their configuration.
-
Patent examiners scrutinize for obviousness given existing kinase inhibitor structures.
-
Broad claims can be challenged but are often supported by extensive data demonstrating utility and inventive step.
Key Takeaways
-
U.S. Patent 10,722,456 claims specific heterocyclic kinase inhibitors with a defined core structure and substitution pattern.
-
The patent's protection covers chemical compounds, their synthesis, and therapeutic use, with scope limited by structural specificity.
-
The patent landscape around kinase inhibitors is crowded, with overlapping claims requiring detailed freedom-to-operate analysis.
-
Innovators differentiate by specific substitutions, improved pharmacokinetics, or targeted applications.
-
Patent enforcement and licensing opportunities depend on the uniqueness of the claimed compounds and method claims.
FAQs
1. What is the core chemical structure protected by U.S. Patent 10,722,456?
It involves heterocyclic compounds with a pyrimidine or pyridopyrimidine core, modified with specific substituents at designated positions to inhibit kinase activity.
2. How broad are the claims in this patent?
Claims cover a range of compounds with variations in substituents, but they are limited by the core structure and specific substitutions disclosed.
3. Does the patent cover only compounds, or does it include treatment methods?
It includes both the compounds themselves and methods for using the compounds to treat diseases such as cancer.
4. What is the patent landscape relevance for licensing or R&D?
The landscape is dense with similar kinase inhibitor patents; FTO analyses are essential to avoid infringement and identify patent gaps.
5. How does this patent compare to prior art?
It offers specific structural modifications that distinguish it from earlier kinase inhibitors but still faces challenges regarding obviousness due to prior heterocyclic kinase inhibitors.
References
[1] United States Patent and Trademark Office. U.S. Patent 10,722,456.
[2] WIPO Patent Application WO2019112233.
[3] PubMed, “Kinase inhibitor patents,” (2022).
[4] LexisNexis PatentSight, “Global kinase inhibitor patent landscape,” (2022).
